Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy

Completed · Phase 2

Conditions studied: Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Neutropenia, Sarcoma

In brief

RATIONALE: Voriconazole may be effective in preventing systemic fungal infections following chemotherapy. PURPOSE: Phase II trial to study the effectiveness of voriconazole in preventing systemic fungal infections in children who have neutropenia after receiving chemotherapy for leukemia, lymphoma, or aplastic anemia or in preparation for bone marrow or stem cell transplantation.

Key facts

Study ID

NCT00066599

Run by

National Cancer Institute (NCI)

Starts

2003-06-01

Expected to finish

2004-06-01

Last updated by the study team

2013-06-19

Who can join

Age: 2 and older, up to 11. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Children's Hospital of Orange County — Orange, California, United States
• Children's Hospital and Health Center, San Diego — San Diego, California, United States
• Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support — Bethesda, Maryland, United States
• Duke Comprehensive Cancer Center — Durham, North Carolina, United States
• Ireland Cancer Center — Cleveland, Ohio, United States
• Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States
• Simmons Cancer Center at University of Texas Southwestern Medical Center - Dallas — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.